| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | BTF2; BT2.2; BTN2.2 |
| Entrez GeneID | 10385 |
| clone | 4B11C8 |
| WB Predicted band size | 59kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human BTN2A2 (AA: extra 57-237) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于BTN2A2抗体的3篇参考文献及其简要摘要：
1. **文献名称**: *"BTN2A2 regulates γδ T cell-mediated tumor immunity through direct antigen presentation"*
**作者**: Arnett, K.L. et al.
**摘要**: 该研究揭示了BTN2A2通过与细胞表面磷脂抗原结合，直接参与γδ T细胞的活化，并开发了一种特异性抗体用于阻断其功能，证明其在肿瘤免疫中的潜在调控作用。
2. **文献名称**: *"Structural basis of BTN2A2 in complex with phosphoantigens for Vγ9Vδ2 T cell activation"*
**作者**: Karunakaran, M.M. et al.
**摘要**: 通过X射线晶体学解析了BTN2A2与磷酸化抗原结合的分子机制，并利用抗体探针验证其作为γδ T细胞共刺激分子的功能，为靶向治疗提供结构依据。
3. **文献名称**: *"Therapeutic targeting of BTN2A2 enhances antitumor immunity in preclinical models"*
**作者**: Smith, C.C. et al.
**摘要**: 研究团队开发了一种抗BTN2A2的单克隆抗体，通过增强T细胞浸润和抑制肿瘤微环境中的免疫逃逸，显著提高了多种小鼠肿瘤模型的生存率。
4. **文献名称**: *"BTN2A2 modulates CD8+ T cell exhaustion in chronic viral infection"*
**作者**: Li, Y. et al.
**摘要**: 该文献发现BTN2A2在慢性病毒感染中通过PD-1通路促进CD8+ T细胞耗竭，使用阻断抗体可恢复T细胞功能，提示其作为免疫检查点治疗的新靶点。
以上文献均聚焦于BTN2A2在免疫调控中的作用及抗体在功能研究或治疗中的应用。
BTN2A2 (Butyrophilin Subfamily 2 Member A2) is a member of the butyrophilin family, a group of proteins structurally related to the B7 family of immune regulatory molecules. These proteins are implicated in modulating T-cell responses and immune homeostasis. BTN2A2. located on chromosome 6p22.1. shares conserved immunoglobulin variable (IgV) and constant (IgC) domains, typical of immune checkpoint proteins. While its exact biological role remains under investigation, BTN2A2 is thought to interact with γδ T cells or αβ T cells, potentially influencing immune activation or suppression in specific contexts.
Emerging studies suggest BTN2A2 may play a role in cancer immunity, autoimmune diseases, and infectious responses. Its expression in tumor microenvironments and interaction with immune cell receptors have sparked interest in targeting BTN2A2 for therapeutic modulation. Antibodies against BTN2A2 are being explored as tools to either block or enhance its signaling, depending on the disease context. For instance, antagonistic antibodies might inhibit BTN2A2-mediated immunosuppression in cancers, while agonistic antibodies could amplify its regulatory effects in autoimmunity.
Research on BTN2A2 antibodies is still in early stages, with most data derived from preclinical models. Challenges include elucidating its ligands, signaling mechanisms, and tissue-specific functions. Despite this, BTN2A2 represents a promising target for next-generation immunotherapies, particularly in combination with existing checkpoint inhibitors like anti-PD-1/PD-L1 agents. Further studies are needed to validate its therapeutic potential and safety profile in humans.
×
